JPMorgan China Region Fund, Inc. (NYSE:JFC) Files An 8-K Regulation FD Disclosure

JPMorgan China Region Fund, Inc. (NYSE:JFC) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure

Story continues below

Item 9.01. Financial Statements and Exhibits

Exhibit Index: June 2017 Monthly Review of the Fund’s performance by the Fund’s investment adviser

Item 7.01 Regulation FD Disclosure

to Regulation FD Rules 100-103, the JPMorgan China Region Fund, Inc. (the “Fund”) furnishes the Monthly Review of the Fund’s performance by the Fund’s investment adviser.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description
June 2017 Monthly Review of the Fund’s performance by the Fund’s investment adviser


JPMORGAN CHINA REGION FUND, INC. Exhibit
EX-99.1 2 ex99-1.htm EX-99.1   BenchmarkA Performance data (as at 30/06/17) 80 ! MSCI Golden Dragon Index (Net) 400 20 ! CSI 300 Index (Net) 350 300 Investment objective 250 200 Long term capital appreciation through investments 150 primarily in equity securities of companies with 100 substantial assets in,…
To view the full exhibit click here

About JPMorgan China Region Fund, Inc. (NYSE:JFC)

JPMorgan China Region Fund, Inc. is a non-diversified closed-end management investment company. The Fund seeks to achieve long-term capital appreciation through investments primarily in equity securities of companies with substantial assets in, or revenues derived from, China, Hong Kong, Taiwan and Macau (collectively the China Region). The Fund invests in various industries, including aerospace and defense, airlines, automobiles, banks, beverages, capital markets, chemicals, commercial services and supplies, construction and engineering, diversified consumer services, diversified telecommunication services, health care providers and services, hotels, restaurants and leisure, independent power and renewable electricity producers, insurance, Internet software and services, leisure products, machinery, media, food and staples retailing, gas utilities and pharmaceuticals. The Fund’s investment advisor is JF International Management Inc., an indirect subsidiary of JPMorgan Chase & Co.

An ad to help with our costs